Actualités Associées Actualités Associées Market Talk Actualités Résultats Principaux Mouvements du Marché Acquisitions, Fusions, Rachats
10 sept. 2024, 09:29 UTC
Principaux Mouvements du Marché
AstraZeneca Shares Slump After Cancer Drug Misses Key Target
25 juil. 2024, 09:17 UTC
AstraZeneca Raises Guidance After Results Beat Market Expectations -- Update
25 juil. 2024, 06:48 UTC
AstraZeneca Raises Guidance After Revenue, Earnings Beat Market Expectations
12 sept. 2024, 17:01 UTC
The Brawl Taking Shape Over Pfizer's Multibillion-Dollar Heart Monopoly -- Heard on the Street -- Update
12 sept. 2024, 11:00 UTC
The Brawl Taking Shape Over Pfizer's Multibillion-Dollar Heart Monopoly -- Heard on the Street -- WSJ
10 sept. 2024, 13:08 UTC
AstraZeneca's Lung Cancer Drug Candidate Disappoints, Lowering Probability of FDA Approval -- Market Talk
9 sept. 2024, 07:56 UTC
Big Pharma's Stability in Return on R&D Investment Is Encouraging -- Market Talk
5 sept. 2024, 13:00 UTC
China Detains AstraZeneca Employees Over Alleged Transport of Unapproved Drug -- WSJ
29 juil. 2024, 10:30 UTC
Big Pharma Rallies and Moves Past Obesity -- Heard on the Street -- WSJ
25 juil. 2024, 13:20 UTC
AstraZeneca Slides Despite Beating Quarterly Expectations And Hiking Its Outlook -- IBD
25 juil. 2024, 09:21 UTC
AstraZeneca's Guidance Lift Is Conservative; Risks to Upside -- Market Talk
25 juil. 2024, 07:05 UTC
AstraZeneca Guidance Raise Signals Portfolio Potential -- Market Talk
25 juil. 2024, 06:06 UTC
AstraZeneca Increased Interim Dividend by 7c to $1.00
25 juil. 2024, 06:04 UTC
AstraZeneca Had Seen Core EPS Grow by Low Double-Digit to Low Teens Percentage Range
25 juil. 2024, 06:04 UTC
AstraZeneca Had Seen Total Revenue Grow by Low Double-Digit to Low Teens Percentage Range
25 juil. 2024, 06:04 UTC
AstraZeneca Sees Core EPS Growth in 2024 by Mid Teens Percentage Range At Constant Currency
25 juil. 2024, 06:04 UTC
AstraZeneca Sees Total Revenue Growth in 2024 by Mid Teens Percentage Range At Constant Currency
25 juil. 2024, 06:03 UTC
AstraZeneca Raises 2024 View
25 juil. 2024, 06:02 UTC
AstraZeneca 2Q Revenue Consensus Was $12.7B
25 juil. 2024, 06:02 UTC
AstraZeneca 2Q Core EPS Consensus Was $1.95
25 juil. 2024, 06:00 UTC
AstraZeneca PLC 2Q Adj EPS $1.98
25 juil. 2024, 06:00 UTC
AstraZeneca PLC 2Q Pretax Pft $2.4B
25 juil. 2024, 06:00 UTC
AstraZeneca PLC 2Q Rev $12.94B
25 juil. 2024, 06:00 UTC
AstraZeneca PLC 2Q Oper Pft $2.75B
25 juil. 2024, 06:00 UTC
AstraZeneca PLC 2Q Net Pft $1.93B
25 juil. 2024, 06:00 UTC
AstraZeneca PLC 2Q EPS $1.24
15 juil. 2024, 06:04 UTC
Acquisitions, Fusions, Rachats
AstraZeneca: Amolyt Pharma's Hldrs Eligible to Receive $250M On Achieving Specific Milestone
15 juil. 2024, 06:04 UTC
Acquisitions, Fusions, Rachats
AstraZeneca: Amolyt Pharma's Hldrs Eligible to Receive $250M On Achieving Specific Milestone
15 juil. 2024, 06:02 UTC
Acquisitions, Fusions, Rachats
AstraZeneca: Acquisition Includes $800M Upfront at Deal Closing
15 juil. 2024, 06:02 UTC
Acquisitions, Fusions, Rachats
AstraZeneca: Amolyt Pharma's Total Consideration of Up to $1.05B
AstraZeneca PLC ADR
